The study aim to assess demographic and clinical characteristics , treatment patterns and as exploratory analysis will descriptively assess the time to clinical events of NVAF patients treated with oral anticoagulants (OACs) in Colombia through observational, descriptive study of a retrospective cohort of adult patients diagnosed with NVAF in selected Health Maintenance Organizations (HMO) of Colombia. The information will be used in the study comes exclusively form secondary sources: claim databases and medical records.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Time to Diagnose NVAF by Each OAC Treatment
Timeframe: At index date (anytime between 01-January-2013 to 30-June-2018)
Number of Participants With Comorbidities
Timeframe: From index date until switch of treatment, discontinuation, death, first stroke/systemic embolism, or major bleeding, or until end of follow-up, whichever occurred first anytime between Jan 2013 to Jul 2019(approximately 6.5 years)
Number of Participants With Uncontrolled Hypertension at OAC Prescription Date
Timeframe: At index date (any time between 01-January-2013 to 30-June-2018)
Number of Participants With Use of Aspirin at Start OAC Treatment
Timeframe: At index date (anytime between 01-January-2013 to 30-June-2018)
Number of Participants With Use of Clopidogrel at Start of OAC Treatment
Timeframe: At index date (anytime between 01-January-2013 to 30-June-2018)
Number of Participants With Use of Non-Steroidal Anti-Inflammatory Drugs at Start of OAC Treatment
Timeframe: At index date (anytime between 01-January-2013 to 30-June-2018)
HAS-BLED Score at Start of OAC Treatment
Timeframe: At index date (anytime between 01-January-2013 to 30-June-2018)
CHA2DS2-VASc Score at Start of OAC Treatment
Timeframe: At index date (anytime between 01-January-2013 to 30-June-2018)
Number of Participants With Anemia at Start of OAC Treatment
Timeframe: At index date (anytime between 01-January-2013 to 30-June-2018)
Number of Participants With Stroke
Timeframe: From index date until switch of treatment, discontinuation, death, first stroke/systemic embolism, or major bleeding, or until end of follow-up, whichever occurred first anytime between Jan 2013 to Jul 2019(approximately 6.5 years)
Duration of Follow-up in Participants With Stroke
Timeframe: From index date until switch of treatment, discontinuation, death, first stroke/systemic embolism, or major bleeding, or until end of follow-up, whichever occurred first anytime between Jan 2013 to Jul 2019(approximately 6.5 years)
Number of Participants According to Type of Stroke
Timeframe: From index date until switch of treatment, discontinuation, death, first stroke/systemic embolism, or major bleeding, or until end of follow-up, whichever occurred first anytime between Jan 2013 to Jul 2019(approximately 6.5 years)
Number of Participants With Pulmonary Embolism
Timeframe: From index date until switch of treatment, discontinuation, death, first stroke/systemic embolism, or major bleeding, or until end of follow-up, whichever occurred first anytime between Jan 2013 to Jul 2019(approximately 6.5 years)
Duration of Follow-up in Participants With Pulmonary Embolism
Timeframe: From index date until switch of treatment, discontinuation, death, first stroke/systemic embolism, or major bleeding, or until end of follow-up, whichever occurred first anytime between Jan 2013 to Jul 2019(approximately 6.5 years)
Number of Participants With Gastrointestinal Bleeding
Timeframe: From index date until switch of treatment, discontinuation, death, first stroke/systemic embolism, or major bleeding, or until end of follow-up, whichever occurred first anytime between Jan 2013 to Jul 2019(approximately 6.5 years)
Duration of Follow-up in Participants With Gastrointestinal Bleeding
Timeframe: From index date until switch of treatment, discontinuation, death, first stroke/systemic embolism, or major bleeding, or until end of follow-up, whichever occurred first anytime between Jan 2013 to Jul 2019(approximately 6.5 years)
Number of Participants With Intracranial Bleeding
Timeframe: From index date until switch of treatment, discontinuation, death, first stroke/systemic embolism, or major bleeding, or until end of follow-up, whichever occurred first anytime between Jan 2013 to Jul 2019(approximately 6.5 years)
Duration of Follow-up in Participants With Intracranial Bleeding
Timeframe: From index date until switch of treatment, discontinuation, death, first stroke/systemic embolism, or major bleeding, or until end of follow-up, whichever occurred first anytime between Jan 2013 to Jul 2019(approximately 6.5 years)
Number of Deaths
Timeframe: From index date until death or until end of follow-up, whichever occurred first anytime between Jan 2013 to Jul 2019(approximately 6.5 years)
Duration of Follow-up in Participants Who Died
Timeframe: From index date until death or until end of follow-up, whichever occurred first anytime between Jan 2013 to Jul 2019(approximately 6.5 years)
Time Under OAC Treatment (Persistence) by Each OAC Treatment
Timeframe: From index date until switch of treatment, discontinuation, or until end of follow-up, whichever occurred first anytime between Jan 2013 to Jul 2019(approximately 6.5 years)
Number of Participants With Other Major Bleeding
Timeframe: From index date until switch of treatment, discontinuation, death, first stroke/systemic embolism, or major bleeding, or until end of follow-up, whichever occurred first anytime between Jan 2013 to Jul 2019(approximately 6.5 years)
Duration of Follow-up in Participants With Other Major Bleeding
Timeframe: From index date until switch of treatment, discontinuation, death, first stroke/systemic embolism, or major bleeding, or until end of follow-up, whichever occurred first anytime between Jan 2013 to Jul 2019(approximately 6.5 years)
Dose of Initial OAC Prescription by Each OAC Treatment
Timeframe: At index date (anytime between 01-January-2013 to 30-June-2018)
Number of Doses Dispensed at Initial OAC Treatment by Each OAC Treatment
Timeframe: At index date (anytime between 01-January-2013 to 30-June-2018)
Number of Participants With Dose Reduction by Each OAC Treatment
Timeframe: From baseline (index date) until switch of treatment, discontinuation, death, first stroke/systemic embolism, or major bleeding, or until end of follow-up, whichever occurred first anytime between Jan 2013 to Jul 2019(approximately 6.5 years)
Time to Dose Reduction by Each OAC Treatment
Timeframe: From index date until date of dose reduction or until end of follow-up, anytime between Jan 2013 to Jul 2019(approximately 6.5 years)
Number of Participants With Treatment Discontinuation
Timeframe: From index date until date of discontinuation, or until end of follow-up, whichever occurred first anytime between Jan 2013 to Jul 2019(approximately 6.5 years)
Time to Discontinuation
Timeframe: From index date until date of discontinuation, or until end of follow-up, whichever occurred first anytime between Jan 2013 to Jul 2019(approximately 6.5 years)
Number of Participants According to Reasons for Discontinuation
Timeframe: From index date until switch of treatment, discontinuation, death, first stroke/systemic embolism, or major bleeding, or until end of follow-up, whichever occurred first anytime between Jan 2013 to Jul 2019(approximately 6.5 years)
Number of Participants According to INR Measurements During Follow-up (Warfarin Group Only)
Timeframe: From 1 Month to maximum 6.5 years (Jan 2013 to Jul 2019)
Number of Participants Who Switched to Another OAC Treatment
Timeframe: From index date until switch of treatment or until end of follow-up, whichever occurred first anytime between Jan 2013 to Jul 2019(approximately 6.5 years)
Time to Switch to Another OAC Treatment
Timeframe: From index date until switch of treatment or until end of follow-up, whichever occurred first anytime between Jan 2013 to Jul 2019(approximately 6.5 years)
Number of Participants According to Reasons for Switching OAC Treatment
Timeframe: From index date until switch of treatment, or until end of follow-up, whichever occurred first anytime between Jan 2013 to Jul 2019(approximately 6.5 years)
Number of Participants With Concomitant Therapies by OAC Prescription
Timeframe: From index date until switch of treatment, discontinuation, death, first stroke/systemic embolism, or major bleeding, or until end of follow-up, whichever occurred first anytime between Jan 2013 to Jul 2019(approximately 6.5 years)
Number of Participants Who Were Previously Exposed to Warfarin (NOACs Group Only)
Timeframe: Up to 6 months prior to index date